U.S. End Stage Renal Disease Market Size & Outlook
- MedTech
- Nephrology Devices
- End Stage Renal Disease Market Outlook
- Nephrology Devices
U.S. End Stage Renal Disease Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the end stage renal disease market
U.S. end stage renal disease market highlights
- The U.S. end stage renal disease market generated a revenue of USD 15,950.6 million in 2023 and is expected to reach USD 37,790.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.1% from 2024 to 2030.
- In terms of segment, dialysis was the largest revenue generating treatment type in 2023.
- Dialysis is the most lucrative treatment type segment registering the fastest growth during the forecast period.
End stage renal disease market data book summary
| Market revenue in 2023 | USD 15,950.6 million |
| Market revenue in 2030 | USD 37,790.2 million |
| Growth rate | 13.1% (CAGR from 2023 to 2030) |
| Largest segment | Dialysis |
| Fastest growing segment | Dialysis |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Transplant, Dialysis |
| Key market players worldwide | Nipro Corp, Fresenius SE & Co KGaA, Baxter International Inc, Medtronic PLC, B. Braun, BD, Asahi Kasei Corp, Cantel Medical, Nikkiso Co Ltd, JMS Support Japan |
Other key industry trends
- In terms of revenue, U.S. accounted for 14.3% of the global end stage renal disease market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. end stage renal disease market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 37,790.2 million by 2030.
As per the National Kidney Foundation, CKD has affected around 37 million people in the U.S. CKD is more common in women as compared to that in men.
Furthermore, as per the same source, in 2017, more than 500,000 patients have undergone dialysis and more than 200,000 people are living with a kidney transplant.
Moreover, Medicare cost of the people with all the stages of CKD in 2017 was around USD 120 billion. In 2017, Medicare spent USD 84 billion on people with CKD and USD 36 billion on people with End Stage Kidney Disease (ESKD).
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
End Stage Renal Disease Market Scope
End Stage Renal Disease Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Baxter International Inc | View profile | 60,000 | One Baxter Parkway, Deerfield, IL, United States, 60015 | www.baxter.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Fresenius SE & Co KGaA | View profile | 193,865 | Else-Kroener-Strasse 1, Bad Homburg, HE, Germany, 61352 | www.fresenius.com |
| Asahi Kasei Corp | View profile | 48,897 | 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan, 101-8101 | www.asahi-kasei.co.jp |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | www.bbraun.co.uk |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Nikkiso Co Ltd | View profile | 8,529 | 4-20-3, Ebisu, Shibuya-ku, Tokyo, Japan, 150-6022 | www.nikkiso.co.jp |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | www.bd.com |
| Cantel Medical | View profile | 1001-5000 | Little Falls, New Jersey, United States, North America | www.cantelmedical.com |
| JMS Support Japan | View profile | 11-50 | Tokyo, Tokyo, Japan, Asia | jms-support.jp |
U.S. End Stage Renal Disease Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to End Stage Renal Disease Market Outlook will help companies and investors design strategic landscapes.
Dialysis was the largest segment with a revenue share of 78.13% in 2023.
Horizon Databook has segmented the U.S. end stage renal disease market based on transplant, dialysis covering the revenue growth of each sub-segment from 2018 to 2030.
As per the National Kidney Foundation, CKD has affected around 37 million people in the U.S. CKD is more common in women as compared to that in men.
Furthermore, as per the same source, in 2017, more than 500,000 patients have undergone dialysis and more than 200,000 people are living with a kidney transplant.
Moreover, Medicare cost of the people with all the stages of CKD in 2017 was around USD 120 billion. In 2017, Medicare spent USD 84 billion on people with CKD and USD 36 billion on people with End Stage Kidney Disease (ESKD).
- U.S. End Stage Renal Disease Market Treatment Type Outlook (Revenue, USD Million , 2018-2030)
- Transplant
- Dialysis
Reasons to subscribe to End Stage Renal Disease Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of End Stage Renal Disease Market Outlook databook
- Our clientele includes a mix of End Stage Renal Disease Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. End Stage Renal Disease Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. End Stage Renal Disease Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. End Stage Renal Disease Market, 2018-2030 (US$M)
U.S. end stage renal disease market statistics, by treatment type, 2018-2030 (US$M)
